Kala’s dry eye disease candidate KPI-121 meets objective in STRIDE 3 trial

This article was originally published here

Planned to be branded as EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25%, KPI-121 showed statistically significant results for primary and also key secondary endpoints in comparison to placebo in

The post Kala’s dry eye disease candidate KPI-121 meets objective in STRIDE 3 trial appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply